Overview

* Pulmonx ( LUNG ) Q2 revenue rises 15% yr/yr to $23.9 mln, beating analyst expectations

* International revenue grows 32% yr/yr, while U.S. revenue increases 6%

* Company revises full-year revenue guidance downwards due to U.S. revenue conversion delays

Outlook

* Pulmonx ( LUNG ) lowers 2025 revenue guidance to $90 mln-$92 mln

* Company expects 2025 gross margin to be about 74%

* Pulmonx ( LUNG ) revises 2025 operating expenses to $128 mln-$130 mln

* Company's guidance excludes impact from future tariffs or trade changes

Result Drivers

* INTERNATIONAL PERFORMANCE - Strong international revenue growth of 32% yr/yr contributed significantly to overall revenue increase

* ADVERTISING IMPACT - Targeted Direct-to-Patient advertising drove over 20,000 first-time patient engagements

* EXPANSION - Addition of 12 new U.S. treatment centers and training of 26 new physicians supported growth

Key Details

Metric Beat/Mis Actual Consensu

s s

Estimate

Q2 Beat $23.86 $23.50

Revenue mln mln (6

Analysts

)

Q2 EPS -$0.38

Q2 Net -$15.17

Income mln

Q2 Gross $17.20

Profit mln

Q2 -$14.80

Income mln

From

Operatio

ns

Q2 -$15 mln

Pretax

Profit

Analyst Coverage

* The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 5 "strong buy" or "buy", 1 "hold" and no "sell" or "strong sell"

* The average consensus recommendation for the medical equipment, supplies & distribution peer group is "buy"

* Wall Street's median 12-month price target for Pulmonx Corp ( LUNG ) is $13.50, about 77.1% above its July 29 closing price of $3.09

Press Release:

(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)